Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis

Pediatric Blood and Cancer

Volumn 44, Issue 3, 2005, Pages 251-254

  Jordan, Michael B ^a   McClain, Kenneth L ^b,e   Yan, Xiaotian ^b   Hicks, John ^c   Jaffe, Ronald ^d  

^a CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Alemtuzumab; Campath; CD52; Langerhans cell histiocytosis

Indexed keywords

ALEMTUZUMAB; CAMPATH 1G; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BINDING; DRUG DETERMINATION; FROZEN SECTION; HISTIOCYTOSIS X; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; PRIORITY JOURNAL; TISSUE SLICE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; GLYCOPROTEINS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LANGERHANS CELLS;

EID: 13444283296     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20181     Document Type: Article

References (21)

1. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-127.
2. Xia MQ, Tone M, Packman L, et al. Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991;21:1677-1684.
3. Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-640.
4. Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002;99:2586-2591.
5. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 2001;3:197-201.
6. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773.
7. McClain KL, Hutter JJ, Cassady JR. Langerhan's cell histiocytosis. In: JR C, editor. Radiation therapy in pediatric oncology. New York: Springer-Verlag; 1994. pp 337-350.
8. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001;97:1241-1248.
9. Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator. Med Pediatr Oncol 2002;39:581-585.
10. Willman CL, McClain KL. An update on clonality, cytokines, and viral etiology in Langerhans-cell histiocytosis. Hematol Oncol Clin North Am 1998;12:407-416.
11. Laman JD, Leenen PJ, Annels NE, et al. Langerhans-cell histiocytosis 'insight into DC biology.' Trends Immunol 2003;24:190-196.
12. Emile JF, Fraitag S, Leborgne M, et al. Langerhans' cell histiocytosis cells are activated Langerhans' cells. J Pathol 1994;174:71-76.
13. de Graaf JH, Tamminga RY, Kamps WA, et al. Langerhans' cell histiocytosis: Expression of leukocyte cellular adhesion molecules suggests abnormal homing and differentiation. Am J Pathol 1994;144:466-472.
14. Annels NE, da Costa CET, Prins FA, et al. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 2003;197:1385-1390.
15. Fleming MD, Pinkus JL, Fournier MV, et al. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood 2003;101:2473-2475.
16. Chu T, Jaffe R. The normal Langerhans cell and the LCH cell. Br J Cancer Suppl 1994;23:S4-S10.
17. Pinkus GS, Lones MA, Matsumura F, et al. Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker. Am J Clin Pathol 2002;118:335-343.
18. Ratzinger G, Reagan JL, Heller G, et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003;101:1422-1429.
19. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002;100:1715-1720.
20. Salisbury JR, Rapson NT, Codd JD, et al. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkins lymphomas. J Clin Pathol 1994;47:313-317.
21. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fudarabine: Results of a large international study. Blood 2002;99:3554-3561.